{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-22-011124","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.630314+00:00","generated_at":"2026-06-22T05:14:04.303043+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix Q3 net loss widens to $29M on higher R&D spend; cash at $140M","bullets":["Net loss $29.0M ($0.69/sh) vs $18.5M ($1.60/sh) in Q3 2021; share count rose to 41.9M from 11.6M.","Cash and equivalents $140M at Sept 30, 2022, down from $178.7M at Dec 31, 2021.","R&D expenses $22.2M in Q3 2022 vs $13.1M in Q3 2021, driven by clinical and manufacturing costs.","Raised $15.0M in Oct 2022 via private placement of Series A/B convertible redeemable preferred stock.","Interim data from Phase 3 fibromyalgia and Phase 2 Long COVID TNX-102 SL studies expected in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-22-011124","json":"https://secwatch.observer/filing/0001387131-22-011124.json","markdown":"https://secwatch.observer/filing/0001387131-22-011124.md","text":"https://secwatch.observer/filing/0001387131-22-011124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/0001387131-22-011124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/tnxp-8k_110722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:14:04.303043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8a7bfecc8a7a2aced610c54eb343a13d0c50e03","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/0001387131-22-011124-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}